CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-11-30): Resectable colorectal liver metastases don't need preop chemo

Clinical

Resectable colorectal liver metastases don't need preop chemo

Last Updated: 2011-11-30 16:11:15 -0400 (Reuters Health)

NEW YORK (Reuters Health) - When colorectal cancer spreads to the liver, chemotherapy can help shrink inoperable tumors -- but if the liver lesions can be resected, then neoadjuvant chemo adds no benefit, a new review article shows.

This month in Annals of Surgery, Dr. Pierre-Alain Clavien and colleagues at University Hospital Zurich, Switzerland say the value of chemotherapy before hepatic resection of colorectal metastases should be analyzed for two distinct indications: reducing unresectable lesions to resectable status, and as neoadjuvant therapy in patients presenting with resectable tumors.

To assess the risks and benefits of chemo in these scenarios, the authors reviewed clinical articles in English on the topic.

For downsizing, based on a selection of 20 relevant articles, the team concludes that chemotherapy can result in a resectability rate of about 30%, although many regimens are associated with numerous side effects.

In the case of clearly resectable lesions, the authors argue that the only justification for neoadjuvant chemotherapy should be a significant improvement in disease-free and overall survival. They failed to find that in their review of 14 studies.

For example, in the only randomized trial addressing the issue, an increase in progression-free survival at three years with neoadjuvant therapy did not lead to increased overall survival, and rates of steatohepatitis or obstruction syndrome were higher in patients receiving neoadjuvant therapy.

Also, in retrospective studies analyzed, adjuvant therapy after surgery was linked with improved survival but neoadjuvant chemotherapy was not.

Summing up, Dr. Clavien and colleagues conclude: "Taken together, the data indicate that for unresectable liver metastases, downsizing chemotherapy may offer a chance for secondary resection in about a third of patients ... In contrast, routine neoadjuvant chemotherapy cannot be recommended due to the increased risk of complications without clear benefit on survival."

SOURCE: http://bit.ly/tLTQOd

Ann Surg 2011.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.